|
|
|
|
07/30/10 |
Geron to Proceed with First Human Clinical Trial of
Embryonic Stem Cell-Based Therapy |
|
|
|
|
07/28/10 |
Abbott Fund-Sponsored Laboratory Training Initiative
Helps Stem Critical Shortage of Medical Professionals in California |
|
|
|
|
07/23/10 |
Sandoz leads the way with first generic version of 'gold
standard' anti-thrombotic Lovenox®[1] |
|
|
|
|
07/20/10 |
Genentech Provides Update From Avastin FDA Advisory
Committee Meeting |
|
|
|
|
|
Lilly Announces Completion of Alnara Acquisition |
|
|
|
|
07/15/10 |
Geron Provides Update on Telomerase Activation Program |
|
|
|
|
07/07/10 |
Geron Presents Clinical Data on Its Telomerase Inhibitor
Drug in Breast Cancer at ASCO |
|
|
|
|
07/06/10 |
Genentech Submits Application to FDA for Trastuzumab-DM1
in Previously Treated Advanced HER2-Positive Breast Cancer |
|
|
|
|
07/01/10 |
Genentech: Second Phase III Study Showed
Avastin-Containing Regimen Helped Women with Ovarian Cancer Live Longer
Without their Disease Getting Worse |
|
|
|
|
06/05/10 |
BMS:
SPRYCEL® (dasatinib) Demonstrates Superior Confirmed
Complete Cytogenetic Response Rates Compared to Gleevec®* in Study of
Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic
Phase |
|
|
|
|
|
BMS:
Investigational Compound Ipilimumab Demonstrates Improved
Overall Survival in Phase 3 Trial of Previously-Treated Patients with
Metastatic Melanoma |
|
|
|
|
06/04/10 |
New data at ASCO show Novartis drug Tasigna® surpasses
Glivec® in slowing disease progression for newly diagnosed CML patients |
|
|
|
|
06/03/10 |
Abbott Receives FDA Clearance for New Ovarian Cancer Test |
|
|
|
|
06/02/10 |
Pivotal Phase III trial of Novartis drug Afinitor® met
primary endpoint in study of patients with advanced pancreatic
neuroendocrine tumors |
|
|
|
|
|
GSK announces revised product labels for Serevent and
Advair |
|
|
|
|
05/30/10 |
Myriad Genetics:
Federal District Court Rules Isolated DNA Claims are Not
Patentable |
|
|
|
|
05/24/10 |
Bruker:
New autoflex speed System Offers High-Throughput Option
for MALDI Biotyper Microbial Identification |
|
|
|
|
05/19/10 |
Geron Annonces Positive Data on its Small Molecule
Telomerase Activator in Model of Idiopathic Pulmonary Fibrosis |
|
|
|
|
05/07/10 |
Bayer Schering Pharma Initiates Phase III Trial of
Regorafenib in Metastatic Colorectal Cancer » more |
|
|
|
|
|
GSK Statement on FDA Advisory Committee meeting on
Rotavirus vaccines |
|
|
|
|
05/06/10 |
Lilly:
BYDUREON (TM) FDA Review Timeline Set with PDUFA Action
Date of October 22, 2010 |
|
|
|
|
05/05/10 |
Royal Government of Bhutan, Merck and Australian Cervical
Cancer Foundation Partner on Vaccination Program with GARDASIL®
for Girls and Young Women of Bhutan |
|
|
|
|
05/04/10 |
Bristol-Myers Squibb Announces Authorization of Up to $3
Billion Share Repurchase Program |
|
|
|
|
|
Myriad Announces Stock Repurchase Program |
|
|
|
|
05/03/10 |
Abbott Receives FDA Approval for CREON® to Include Dosing
Information for Patients with Chronic Pancreatitis and Pancreatectomy |
|
|
|
|
|
Thermo Fisher Scientific Announces Redemption of 6 1/8%
Senior Subordinated Notes due 2015 |
|
|
|
|
04/22/10 |
Apr 22, 2010
Genentech Submits Supplemental Application to FDA for Herceptin in
Advanced HER2-Positive Stomach Cancer |
|
|
|
|
|
Amylin, Lilly and Alkermes Submit Reply to FDA Complete
Response Letter for BYDUREON(TM) |
|
|
|
|
04/13/10 |
Novartis investigational multiple sclerosis therapy
Gilenia®* (FTY720) shown to reduce relapse rates regardless of treatment
history |
|
|
|
|
|
|
|
04/8/10 |
Seattle Genetics, Takeda and Millennium Announce
Initiation of Phase III AETHERA Trial of Brentuximab Vedotin (SGN-35)
for Post-Transplant Hodgkin Lymphoma |
|
|
|
|
|
Millennium Announces First Clinical Data For TAK-700
Prostate Molecule At ASCO GU |
|
|
|
|
|
Abbott Acquisition of Facet Biotech Clears U.S. Antitrust
Review |
|
|
|
|
03/18/10 |
Novartis receives approval in the European Union for
Menveo®, first quadrivalent conjugate vaccine in the EU to help prevent
meningococcal disease |
|
|
|
|
03/17/10 |
BMS:
U.S. Food And Drug Administration Accepts New Drug
Application For Once-Daily Fixed Dose Combination Of Onglyza™ (Saxagliptin)
And Extended Release Metformin For The Treatment Of Type 2 Diabetes
Mellitus In Adults |
|
|
|
|
|
Statement From Eli Lilly and Company Regarding Stolen
Company Products From Enfield, Connecticut Distribution Operations
|
|
|
|
|
03/16/10 |
Genentech Submits Supplemental Biologics License
Application for ACTEMRA (tocilizumab) for Prevention of Structural Joint
Damage and Improvement of Physical Function in Rheumatoid Arthritis |
|
|
|
|
|
WHO Extends Prequalification of Merck's ROTATEQ® for
Global Use |
|
|
|
|
03/15/10 |
Caliper Settles Outstanding Litigation with Shimadzu |
|
|
|
|
03/12/10 |
Roche provides update on phase III study of Avastin in
men with late stage prostate cancer |
|
|
|
|
|
GSK commences succession plan for management of vaccines
business |
|
|
|
|
|
CV Therapeutics' Board of Directors Rejects Astellas'
Tender Offer |
|
|
|
|
03/09/10 |
Abbott Enhances Pharmaceutical Pipeline with Acquisition
of Facet Biotech |
|
|
|
|
03/08/10 |
Myriad:
Novel Gene Expression Test, PROLARIS(TM), Accurately
Predicts Prostate Cancer Recurrence |
|
|
|
|
|
Roche and Biogen Idec decide to suspend Ocrelizumab
treatment - Rheumatoid Arthritis development programme on hold |
|
|
|
|
03/05/10 |
Thermo Fisher Scientific Completes Acquisition of
Finnzymes |
|
|
|
|
03/03/10 |
Thermo Fisher Scientific Reports Record Revenues in
Fourth Quarter 2009; Initiates Guidance for 2010 |
|
|
|
|
|
Geron Highlights Product Launch From Collaboration with
Corning - The Synthemax™ Surface for Scalable Growth of Human Embryonic
Stem Cells |
|
|
|
|
02/23/10 |
Lilly, Merck, And Pfizer Join Forces To Accelerate
Research And Improve Treatment Of Lung And Gastric Cancers In Asia
|
|
|
|
|
|
Roche:Phase
III study of Avastin plus chemotherapy in advanced stomach cancer did
not meet primary endpoint |
|
|
|
|
|
Life Technologies Launches First Capillary
Electrophoresis Sequencing System Designed for Forensic Laboratories |
|
|
|
|
02/22/10 |
Novartis oral multiple sclerosis development compound
Gilenia®* (FTY720) granted US priority review status |
|
|
|
|
|
Novartis receives FDA approval of Menveo®, a vaccine to
prevent meningococcal disease |
|
|
|
|
|
Agilent Technologies Wins HPLC Columns Trade Secrets Case
Against Advanced Materials Technology, Inc. |
|
|
|
|
02/19/10 |
Roche:
US FDA approves Rituxan/MabThera for the most common type of adult
leukemia |
|
|
|
|
|
|
|
|
|
|
|
MDS Announces Substantial Issuer Bid |
|
|
|
|
|
Life Technologies Announces Completion of $1.5 Billion Senior Notes
Offering |
|
|
|
|
|
GSK Consumer Healthcare warns consumers of potential health risks
associated with long-term excessive use of zinc-containing denture
adhesives |
|
|
|
|
|
Caliper Life Sciences Launches LabChip(R) XT for Next Generation
Sequencing Applications |
|
|
|
|
02/11/10 |
Roche:
Roche study drug may offer valuable new treatment option for patients
with type 2 diabetes |
|
|
|
|
02/10/10 |
MDS Announces Agreements to Divest MDS Pharma Services' Early Stage
Business |
|
|
|
|
02/03/10 |
Thermo Fisher Scientific Reports Record Revenues in Fourth Quarter 2009;
Initiates Guidance for 2010 |
|
|
|
|
02/01/10 |
Thermo Fisher Scientific Signs Agreement to Acquire High-Performance PCR
Solution Provider, Finnzymes |
|
|
|
|
01/25/10 |
MDS Announces Resolution of Litigation Related to the Sale of MDS
Analytical Technologies |
|
|
|
|
01/22/10 |
Vermillion Emerges From Bankruptcy |
|
|
|
|
01/21/10 |
Agilent Technologies' Acquisition of Varian, Inc. Cleared by European
Commission |
|
|
|
|
01/20/10 |
Three new Novartis medicines approved in Japan for patients with type 2
diabetes, high blood pressure and advanced kidney cancer |
|
|
|
|
|
Novartis oral MS therapy FTY720 shows reduced risk of confirmed
disability progression as published in New England Journal of Medicine |
|
|
|
|
01/19/10 |
Thermo Fisher Scientific Signs Agreement to Acquire Leading Innovator in
Handheld Spectrometers, Ahura Scientific |
|
|
|
|
01/12/10 |
GlaxoSmithKline update: Government orders for pandemic
H1N1 vaccine |
|
|
|
|
01/11/10 |
Novartis launches schizophrenia treatment Fanapt in the
US, offering patients an attractive alternative to existing medications |
|
|
|
|
|
Roche:
FDA approves ACTEMRA for the treatment of moderately to
severely active rheumatoid arthritis |
|
|
|
|
|
GSK exercises option to progress development of
ChemoCentryx’s Traficet-EN for the treatment of inflammatory bowel
diseases |
|
|
|
|
|
Caliper Licenses Microfluidics IP to Becton Dickinson |
|
|
|
|
|
Portland,
Oregon - Proteome Software today released its web-based Mass
Spectrometry
Quality Control tool, MassQC. (PDF) |
|
|
|
|
01/08/10 |
Abbott's XIENCE V® Approved in Japan – Second Largest
Drug Eluting Stent Market Worldwide
|
|
|
|
|
01/07/10 |
Vermillion Closes $43.05 Million Private Placement of
Common Stock |
|
|
|
|
|
Bruker Announces Over 100 Systems Orders Received in the
Second Half of 2009 from Global Stimulus Programs |
|
|
|
|
01/06/10 |
Myriad Genetics Partners With Mammography Reporting
Systems to Increase Identification of High Risk Breast Cancer Patients
|
|
01/05/10 |
Geron Announces Publication of Data on its Telomerase
Inhibitor in Glioblastoma |
|
|
|
|
01/04/10 |
Millennium:
FDA Approves Addition of Sustained Overall Survival
Benefit to Label for Velcade® (Bortezomib) for Injection for Patients
with Previously Untreated Multiple Myeloma |
|
|
|
|
12/23/09 |
Novartis to acquire Corthera Inc., gaining worldwide
rights to Phase III project relaxin for treatment of acute decompensated
heart failure |
|
|
|
|
12/21/09 |
All three Novartis A(H1N1) 2009 influenza vaccines
prequalified by World Health Organization (WHO) for use in developing
world |
|
|
|
|
|
Dr. Julie Gerberding Named President of Merck Vaccines |
|
|
|
|
|
Lilly and Incyte Announce Collaboration for Development
and Commercialization of Oral Anti-Inflammatory and Autoimmune Therapies
|
|
|
|
|
12/17/09 |
Merck & Co., Inc. to Acquire Avecia Biologics
|
|
|
|
|
12/15/09 |
Thermo
Fisher Scientific’s mass spectrometry technology helps Children’s
Hospital Boston isolate biomarker for acute pediatric appendicitis.
Children’s Hospital research team believes discovery will lead to more
accurate, efficient diagnosis |
|
|
|
|
|
Biogen Idec Stands Ready to Close Its $17.50 All-Cash
Tender Offer for Facet Biotech |
|
|
|
|
12/14/09 |
GSK publishes speaking, consulting fees paid to US
healthcare professionals |
|
|
|
|
|
U.S. Patent Office Grants Geron's Request for an
Interference with U.S. Patent No. 7,510,876 to Novocell |
|
|
|
|
12/12/09 |
Roche:
Greater chances of cure for patients with HER2-positive
early breast cancer when treated with one year of Herceptin |
|
|
|
|
12/11/09 |
MDS Receives Notice of Application from PerkinElmer, Inc. |
|
|
|
|
12/09/09 |
Novartis set to sustain its leading global position in
oncology with portfolio targeting various tumors and life-threatening
diseases |
|
|
|
|
12/08/09 |
Geron Presents Interim Clinical Data on its Telomerase
Vaccine at the 2009 American Society of Hematology Meeting |
|
|
|
|
12/01/09 |
Merck:
FDA Approves ZEGERID OTC™ for Over-the-Counter Treatment
of Frequent Heartburn |
|
|
|
|
|
Merck:U.S.
Department of Health & Human Services Recommends Merck's First-in-Class
Integrase Inhibitor ISENTRESS® (raltegravir) Tablets, in Combination
Therapy, as a Preferred Regimen for Treatment-Naïve Patients with HIV-1
Infection |
|
|
|
|
11/23/09 |
Merck Wins Summary Judgment in Texas Attorney General's
Lawsuit Involving VIOXX® |
|
|
|
|
|
Pandemic 2009 Influenza Update: Pandemrix™ data in
children and adolescents from 3 to 17 years of age |
|
|
|
|
11/20/09 |
Roche:
European medical advisory committee does not recommend
approval of Avastin for deadly form of brain cancer |
|
|
|
|
|
Merck Receives CHMP Positive Opinion for New Fertility
Treatment, ELONVA® |
|
|
|
|
|
BMS:
U.S. Food and Drug Administration Approves ABILIFY® (aripiprazole)
for the Treatment of Irritability Associated with Autistic Disorder in
Pediatric Patients (Ages 6 to 17 Years) |
|
|
|
|
11/19/09 |
Geron Presents Interim Clinical Data on its Telomerase
Inhibitor Drug at AACR-NCI-EORTC |
|
|
|
|
11/18/09 |
Millennium Initiates First Clinical Trial with The First
Oral Proteasome Inhibitor |
|
|
|
|
|
Genentech and Biogen Idec Receive a Complete Response
from the FDA for Rituxan for Chronic Lymphocytic Leukemia
|
|
|
|
|
11/17/09 |
Novartis Influenza A(H1N1) 2009 vaccine US interim data
show lower doses of antigen may suffice to generate a protective immune
response against A(H1N1) |
|
|
|
|
|
Genentech and Biogen Idec Receive a Complete Response
from FDA for Earlier Use of Rituxan for Rheumatoid Arthritis
|
|
|
|
|
11/16/09 |
Genentech Submits Supplemental Applications to FDA for
Avastin Combined with Commonly Used Chemotherapies for Women with
Advanced Breast Cancer
|
|
|
|
|
|
|
|
11/13/09 |
Novartis receives approval in Switzerland for Celtura®, a
cell culture-based Influenza A(H1N1) pandemic vaccine |
|
|
|
|
|
|
|
11/10/09 |
GSK signs agreement with the WHO to donate 50 million
doses of pandemic H1N1 vaccine for distribution to developing countries |
|
|
|
|
|
Bristol-Myers Squibb and Alder Biopharmaceuticals Enter
Global Agreement on Rheumatoid Arthritis Biologic |
|
|
|
|
11/09/09 |
GSK:
Pandemic 2009 Influenza Update: Pandemrix™ data on
co-administration with annual seasonal influenza vaccine (Fluarix®) |
|
|
|
|
11/06/09 |
World Health Organization Grants Prequalification for
Global Use to GSK’s 10-Valent Synflorix™ Vaccine |
|
|
|
|
11/05/09 |
Novartis receives regulatory approval in Germany for
Celtura®, a cell culture-based Influenza A(H1N1) pandemic vaccine |
|
|
|
|
|
Incyte Reports Third Quarter 2009 Financial Results and
Provides Update on Drug Development Programs |
|
|
|
|
11/04/09 |
Novartis to expand its human vaccines presence in China
through proposed acquisition of a majority stake in Zhejiang Tianyuan |
|
|
|
|
11/03/09 |
Merck and Schering-Plough to Complete Merger Today |
|
|
|
|
|
GSK:World’s
largest malaria vaccine trial now underway in seven African countries |
|
|
|
|
|
Novartis announces USD 1 billion investment to build
largest pharmaceutical R&D institute in China |
|
|
|
|
10/26/09 |
Thermo Fisher Scientific Launches New Biomarker Test in
Europe to Rapidly Diagnose Heart Attack |
|
|
|
|
10/21/09 |
Millennium Initiates Phase II Trial For Diffuse Large
B-Cell Lymphoma |
|
|
|
|
10/15/09 |
Roche reports further accelerated sales growth in third quarter |
|
|
|
|
10/14/09 |
Lilly to Sell Tippecanoe Manufacturing Site to Evonik Industries
|
|
|
|
|
10/13/09 |
Myriad Genetics to Report Fiscal 2010 First Quarter Financial Results On
November 3
|
|
|
|
|
10/12/09 |
Novartis enters into agreement for exclusive US and Canadian rights to
Fanapt(TM), an FDA-approved oral therapy for schizophrenia |
|
|
|
|
10/08/09 |
Novartis gains exclusive worldwide rights to PTK 0796, in Phase III
study as potential first-in-class IV and oral broad-spectrum antibiotic |
|
|
|
|
10/06/09 |
Abbott:
Novel Abbott Test That Aids in the Early Diagnosis of
Acute Kidney Injury (AKI) Receives CE Mark
|
|
|
|
|
|
GSK expands presence in China through strategic
cooperation to form a joint venture on pediatric vaccines |
|
|
|
|
|
GlaxoSmithKline update: Government orders for pandemic
(H1N1) 2009 vaccine |
|
|
|
|
|
Novartis completes shipment of US supply of Fluvirin® seasonal influenza
vaccine |
|
|
|
